Vasotocin derivatives

US4504469A · kind A · utility

Assignee

• Ferring AB · SE

Inventors

• Per Melin · Malmö, SE
• Jerzy Trojnar · Vintrie, SE

Key dates

• Filing date: Dec 15, 1983
• Grant date: Mar 12, 1985
• Expiry date: Dec 15, 2003

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S930/15
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel vasotocin derivatives having an inhibitory effect on uterine contractions, pharmaceutical compositions containing these derivatives, and the use thereof in the therapeutical treatment of excessive muscle contractions in the uterus and described. The derivatives differ from vasotocin in that the structure of the original hormone has been modified at positions 1, 2 and, optionally, 4 and/or 8. The vasotocin derivatives thus have the formula ##STR1## wherein Mpa is a 3-mercaptopropionoyl residue (--S--CH.sub.2 --CH.sub.2 --CO--); PA1 A is the peptide residue of L- or D-tyrosine-O-ethyl ether (in other words, 4-ethoxy-L or D-phenyl alanine, i.e. L- or D-Tyr(Et)), or of a hydrophobic D-amino acid, such as D-tyrosine(D-Tyr) or D-tryptophane(D-Trp); PA1 Ile is the peptide residue of isoleucine; PA1 B is the peptide residue of glutamine (Gln), treonine (Thr) or valine (Val); PA1 Asn is the peptide residue of asparagin; PA1 Cys is the peptide residue of cysteine; PA1 Pro is the peptide residue of proline; PA1 C is the peptide residue of L- or D-arginine (Arg), ornithine (Orn) or citrullin (Cit); and PA1 Gly--NH.sub.2 is the peptide residue of glycine amide.